On Monday, HealthEquity HQY will report its last quarter's earnings. Here is Benzinga's take on the company's release.
Earnings and Revenue
HealthEquity EPS will likely be near 9 cents per share while revenue will be around $58.2 million, according to analysts.
In the same quarter last year, HealthEquity reported earnings per share of 7 cents on sales of $46.8 million. If the company were to match the consensus estimate, earnings would be up 28.57 percent. Sales would be up 24.32 percent on a year-over-year basis.
Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q3 2018 | Q2 2018 | Q1 2018 | Q4 2017 |
| EPS Estimate | 0.13 | 0.14 | 0.16 | 0.05 |
| EPS Actual | 0.17 | 0.21 | 0.19 | 0.07 |
Stock Performance
Over the last 52-week period, shares of HealthEquity are up 30.33 percent. Analysts' have adjusted their estimates higher for EPS and revenues over the past 90 days. Analysts generally rate HealthEquity stock as Neutral. The strength of this rating has maintained conviction over the past three months.
Conference Call
The HealthEquity's Q4 conference call is scheduled to begin at 5:00 p.m. ET and can be accessed here: https://edge.media-server.com/m6/p/a98nrkpq
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
